Limb-Girdle Muscular Dystrophies (LGMDs): The Clinical Application of NGS Analysis, a Family Case Report by C. Strafella et al.
CASE REPORT
published: 13 June 2019
doi: 10.3389/fneur.2019.00619
Frontiers in Neurology | www.frontiersin.org 1 June 2019 | Volume 10 | Article 619
Edited by:
Margherita Milone,
Mayo Clinic, United States
Reviewed by:
Corrado Angelini,
University of Padova, Italy
Zhiyv Neal Niu,
Mayo Clinic, United States
*Correspondence:
Raffaella Cascella
raffaella.cascella@gmail.com
†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Neuromuscular Diseases,
a section of the journal
Frontiers in Neurology
Received: 15 February 2019
Accepted: 28 May 2019
Published: 13 June 2019
Citation:
Strafella C, Campoli G, Galota RM,
Caputo V, Pagliaroli G, Carboni S,
Zampatti S, Peconi C, Mela J,
Sancricca C, Primiano G, Minozzi G,
Servidei S, Cascella R and Giardina E
(2019) Limb-Girdle Muscular
Dystrophies (LGMDs): The Clinical
Application of NGS Analysis, a Family
Case Report. Front. Neurol. 10:619.
doi: 10.3389/fneur.2019.00619
Limb-Girdle Muscular Dystrophies
(LGMDs): The Clinical Application of
NGS Analysis, a Family Case Report
Claudia Strafella 1,2, Giulia Campoli 1, Rosaria Maria Galota 1, Valerio Caputo 1,2,
Giulia Pagliaroli 1, Stefania Carboni 1, Stefania Zampatti 1, Cristina Peconi 1, Julia Mela 1,
Cristina Sancricca 3,4, Guido Primiano 3, Giulietta Minozzi 5, Serenella Servidei 3,
Raffaella Cascella 1,6*† and Emiliano Giardina 1,2†
1Molecular Genetics Laboratory Unione Italiana Lotta Distrofia Muscolare (UILDM), Santa Lucia Foundation, Rome, Italy,
2Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy, 3 Fondazione Policlinico Universitario A.
Gemelli IRCCS, UOC Neurofisiopatologia, Rome, Italy, 4Unione Italiana Lotta Distrofia Muscolare (UILDM), Sezione Laziale,
Rome, Italy, 5Department of Veterinary Medicine, University of Milan, Milan, Italy, 6Department of Biomedical Sciences,
Catholic University Our Lady of Good Counsel, Tirana, Albania
The diagnosis of LGMD2A (calpainopathy) can be challenging due to genetic
heterogeneity and to high similarity with other LGMDs or neuromuscular disorders.
In this setting, NGS panels are highly recommended to perform differential diagnosis,
identify new causative mutations and enable genotype-phenotype correlations. In
this manuscript, the case of a patient affected by LGMD2A is reported, for which
the application of a defined custom designed NGS panel allowed to confirm the
diagnosis of calpainopathy linked with two heterozygous variants in CAPN3, namely
c.550delA and c.1813G>C. The first variant has been extensively described in relation
to calpainopathy. The second variant c.1813G>C, instead, is novel and has been
predicted to be probably damaging. In addition, NGS analysis on the proband revealed
a heterozygous variant (c.550C>T) in the LMNA gene, which is associated with dilated
cardiomyopathy. The variant is novel and has been predicted to be deleterious by
subsequent bioinformatic analysis. Successively, segregation analysis was performed
on family members. Interestingly, none of them showed neuromuscular symptoms but
the mother was diagnosed with bradycardia and syncopal episodes and showed a
positive family history for cardiomyopathy. The segregation analysis reported that the
proband inherited the c.1813G>C (CAPN3) from the father who was a healthy carrier.
The mother was positive for c.550delA (CAPN3) and c.550C>T (LMNA), suggesting
thereby a possible genetic explanation for her cardiovascular problems. Segregation
analysis, therefore, confirmed the inheritance pattern of the variants carried by the
proband and highlighted a familiarity for cardiomyopathy which should not be neglected.
The NGS analysis was further performed on the partner of the proband, to estimate the
reproductive risk of the couple. The partner was negative to NGS screening, suggesting
thereby a low risk to have an affected child with calpainopathy and 50% probability to
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inherit the LMNA variant. This case report showed the clinical utility of the NGS
panel in providing accurate LGMD2A diagnosis and identifying complex phenotypes
originating from mutations in multiple genes. However, NGS results should always be
accomplished by a dedicated genetic counseling, not only to evaluate the recurrence
and reproductive risks but also to uncover unexpected findings which can be
clinically significant.
Keywords: LGMDs, CAPN3, LMNA, NGS panel, familial investigation, calpainopathy, cardiovascular disease
INTRODUCTION
The Limb-Girdle Muscular Dystrophies (LGMDs) include a
heterogenous group of disorders characterized by the progressive
wasting and weakness of the proximal limb-girdles muscles
(1, 2). LGMDs display inter and intrafamilial variability, ranging
from very mild forms, to severe, early onset, rapidly progressive
phenotypes (2). LGMDs can be classified as autosomal dominant
(LGMD1) or recessive (LGMD2). The first group usually has
an adult age of onset and are not very common (<10% of all
LGMDs), whereas the latter are more frequent (1:15000) (1).
Among recessive forms, the LGMD2A (or calpainopathy) is
the most common LGMD worldwide, affecting approximately
30% of all LGMDs cases (3). Clinical signatures of disease
include tiptoe walking, waddling gait, difficulty in running and
climbing stairs, scapular winging. Joint contractures, Achilles
tendon shortening, scoliosis are commonly observed, while
facial and neck muscles are not affected (4). An asymptomatic
HyperCKemia (5–80 times CPK normal levels) in young patients
is considered a preclinical stage of disease and may persist for
several years (1, 5). The age of onset of muscle weakness usually
occurs at 15 years, although it may arise at earlier (<12 years)
or later (>30 years) ages. The disease progression can lead to
loss of ambulation, respiratory insufficiency, and reduced lung
vital capacity in the advanced stages (6). Cardiac involvement
(cardiac rhythm disorders, cardiac conduction disorders,
left ventricular ejection dysfunction) is only occasionally
reported (6, 7).
The diagnosis of calpainopathy is confirmed by the detection
of pathogenic mutations in CAPN3 (15q15.1) (4), encoding
different alternatively spliced transcripts. However, the full-
length transcript is primarily expressed in muscle tissue (8).
The encoded protein (CAPN3) is a member of non-lysosomal
Ca++-dependent cysteine proteases family. In muscle, CAPN3
takes part in “sarcomere remodeling,” which is essential for
muscle adaption and growth in response to functional and
metabolic demands. To date, more than 490 pathogenic
mutations throughout CAPN3 have been described, most of
which are single-nucleotide changes (4). Mutations in CAPN3
have been associated with mitochondrial abnormalities, growth
failure, increased oxidative stress and sarcomere disorganization
which altogether contribute to make the muscle unable to
hold loads, causing thereby myofiber degeneration and muscle
wasting (8). The diagnosis of calpainopathy can be challenging
because of the genetic heterogeneity and the non-specificity
of clinical and instrumental pattern. Indeed, distribution of
muscular weakness/atrophy, hypertrophy/pseudo-hypertrophy,
and tendon contractures are very often shared with other
LGMDs or neuromuscular disorders. Muscle biopsy pattern
in calpainopathy is generally non-specific too, ranging from
mild muscular abnormalities to severe dystrophic changes.
Moreover, immunohistochemical/biochemical markers are
usually not reliable: calpain signal can be normal even in
presence of a non-functional protein, and vice versa it can
be reduced even in other muscular dystrophies different
from calpainopathy.
It is therefore recommended to perform a differential
diagnosis in order to provide accurate and reliable results.
To this purpose, molecular genetic testing approaches have
been developed to confirm the diagnosis of calpainopathy,
including multigene panel, extensive genomic (exome/genome
sequencing) and single-gene analysis (direct sequencing) (9).
The implementation of Next-Generation Sequencing (NGS) was
helpful to generate informative data to be applied to diagnostic,
predictive or therapeutic purposes (10–12). NGS gene panels
are based on the analysis of a set of genes associated with
a specific disease or a group of related disorders, which are
characterized by genetic and phenotypic heterogeneity. NGS
panels can also be useful for detecting blended or complex
phenotypes, which result from the inheritance of more than one
genetic defect from parents (13). In general, patients presenting
complex phenotypes, who are negative to the known mutations
in custom-designed diagnostic gene panels and requiring a
broad differential diagnosis, are eligible for whole exome or
genome sequencing. Whole exome/genome sequencing are
more expensive approaches in terms of data management,
interpretation and analytical costs but increase the likelihood of
providing a molecular diagnosis to a suspected genetic disorder
(13). Concerning LGMDs, dedicated NGS panels are highly
recommended, to ensure high diagnostic rates, optimal coverage,
sensitivity and specificity of clinical testing (9). NGS panels
represent therefore one of the best systems to facilitate differential
diagnosis, identify new causative mutations and clarify genotype-
phenotype correlations (14, 15).
In this manuscript, the case of a patient affected by LGMD2A
is reported, for which the application of the NGS panel allowed
not only to confirm the diagnosis of calpainopathy (mutations
in CAPN3) but also to identify an additional, novel mutation in
LMNA gene associated with dilated cardiomyopathy. Given these
results, the analysis was extended to the family members of the
proband to provide a more comprehensive interpretation of the
analytical data in relation to the pathological phenotypes.
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CASE PRESENTATION
Clinical Characterization of Proband and
Relatives
The onset of disease in the proband was referred at 10 years
of age, when she reports the presence of calf hypertrophy
with tiptoe walking, difficulties in running, climbing stairs,
and standing-up. Symptoms showed a slow but progressive
worsening, with subsequent involvement of proximal upper
limb. At the age of 13, high levels of CPK (∼8,000 UI/L) were
incidentally discovered, never associated with myoglobinuria.
Successively, patient underwent several neuromuscular
investigations at various specialized centers. Two muscular
biopsies were performed, showing classic dystrophic picture
(hypertrophic/atrophic fibers, internal nuclei, necrotic fibers,
increase in connective tissue) with non-specific characteristics.
As expected, immunochemistry and immunoblot studies were
inconclusive indicating abnormal/reduced α, β, γ sarcoglycan,
β-dystroglycan, and dystrophin signal only in necrotic fibers
(repeated immunochemistry resulted normal, also for laminin);
immunoblots for dystrophin and calpain revealed normal
signals. However, the calpain-3 immunoblot is known to be not-
completely sensitive for LGMD2A diagnosis, since 20–30% of
cases display a normal quantity of protein (1, 16–18). Due to the
clinical presentation (hyperCKmia, calf hypertrophy/pseudo-
hypertrophy) dystrophinopathies were firstly ruled out. In
addition, analysis of DMD (Xp21), FKRP (19q13.32), and DYSF
(2p13.2) genes did not reveal pathogenic mutations. Patient
came to our observation at the age of 30, presenting axial
and girdle involvement both in upper and lower limb, with
significant waddling gait and winged scapulae. In lower limbs,
weakness was prominent in quadriceps and glutei muscles which
FIGURE 1 | Proband clinical features: winged scapulae and combination of thigh atrophy and calf pseudo-hypertrophy.
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FIGURE 2 | Proband muscle MRI: involvement of upper limb girdle and paravertebral muscles (A,B), involvement of lower limb girdle and posterior compartment of
the thigh (C–E, mostly the glutei) with relative sparing of the sartorius and gracilis, and involvement of the posterior compartment of the leg (F, mostly gastrocnemius
medialis/soleus).
were significantly ipo-atrophic, together with the evidence of
“apparently hypertrophic” (pseudo-hypertrophy) calf muscles
(Figure 1). Cramps, myalgias, and rippling were not observed.
Complete pneumological (spirometry and polysomnography)
and cardiological (echography, 24-h ECG Holter monitoring,
cardiac MRI, complete cardiological physical inspection with
targeted medical history and cardiovascular reflex analysis)
examinations did not reveal any significant abnormality. We
also ruled out acid maltase deficiency (normal enzyme activity
assays in lymphocytes/leukocytes). Muscle Magnetic Resonance
Imaging (MRI) showed a prominent involvement of scapular
girdle, paravertebral muscles, posterior compartment muscles
of the thigh (with relative sparing of the sartorius and gracilis
muscles) and of the leg (in particular gastrocnemius medialis and
soleus) (Figure 2). This pattern of involvement has already been
reported in literature concerning MRI picture in calpainopathy
(19, 20). In addition, the MRI study showed that calf muscles
were effectively atrophic and characterized by fat infiltration,
causing a muscular “enlargement.” The clinical presentation,
the age of onset, the rate of progression, the distribution of
muscle weakness and the MRI findings in the proband were fully
consistent with a diagnosis of LGMD2A extensively described in
literature (4, 21, 22).
The evaluation of the family members of the proband did not
revealed any history of neuromuscular disease and no evidence
of consanguinity between parents. However, the mother of
the proband, at the age of 55, presented 2 syncopal episodes
for which she was diagnosed with idiopathic bradycardia (up
to 40 bpm by night). Extensive cardiological investigations
on the mother of the proband diagnosed a symptomatic
atrioventricular (AV) block after the occurrence of several
syncopal episodes/lipothymia. The analysis showed the presence
of a basic first-degree AV block, with several periods of
severe bradycardia, mostly nocturnal and often symptomatic,
associated with some phases of second-degree AV block, both
type 1 and 2, and some phases of nocturnal complete AV
dissociation. Echocardiography and ergometric test did not
reveal significant alterations, excepted for the patent foramen
ovale. The mother did not present any other clinical symptom,
predisposing condition or risk factor. Given her clinical picture,
the mother of the proband was implanted with PMK. In addition,
family history revealed that the grandmother and the great-
grandfather of the proband were also implanted with PMK at
the age of 55 and 30 years, respectively. Moreover, the brother
of the grandmother of the proband died at 51 for severe
dilated cardiomyopathy. Cardiological examinations were also
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TABLE 1 | Customized NGS panel utilized for LGMD diagnosis.
Gene OMIM
number
Locus Phenotype (Inheritance) Size of the target
region (bp)
Exon Transcript ID Coverage (%)
DES 125660 2q35 Muscular dystrophy, limb-girdle, type 2R (AR) 2,338 9 ENST00000373960.3 100
DNAJB6 611332 7q36.3 Muscular dystrophy, limb-girdle, type 1E (AD) 3,290 10 ENST00000262177.8 99,91
EMD 300384 Xq28 Emery-Dreifuss muscular dystrophy 1 (XLR) 1,399 6 ENST00000369842.8 100
MYOT 604103 5q31.2 Myopathy, myofibrillar, 3 or Muscular dystrophy,
limb-girdle, type 1A (AD)
2,372 10 ENST00000239926.8 100
LMNA 150330 1q22 Emery-Dreifuss muscular dystrophy 2 or Muscular
dystrophy, limb-girdle, type 1B (AD)
4,274 12 ENST00000368300.8 99,44
CAV3 601253 3p25.3 Muscular dystrophy, limb-girdle, type 1C (AD, AR) 1,451 2 ENST00000343849.2 100
TNPO3 610032 7q32.1. Muscular dystrophy, limb-girdle, type 1F (AD) 4,813 23 ENST00000265388.9 100
CAPN3 114240 15q15.1 Muscular dystrophy, limb-girdle, type 2A (AR) 3,922 24 ENST00000397163.7 100
DYSF 603009 2p13.2 Muscular dystrophy, limb-girdle, type 2B (AR) 7,858 55 ENST00000258104.7 100
SGCG 608896 13q12.12 Muscular dystrophy, limb-girdle, type 2C (AR) 1,735 8 ENST00000218867.3 100
SGCA 600119 17q21.33 Muscular dystrophy, limb-girdle, type 2D (AR) 1,533 10 ENST00000262018.7 100
SGCB 600900 4q12 Muscular dystrophy, limb-girdle, type 2E (AR) 4,339 6 ENST00000381431.9 98,62
SGCD 601411 5q33.2-q33.3 Muscular dystrophy, limb-girdle, type 2F (AR) 10,234 9 ENST00000337851.8 100
TCAP 604488 17q12 Muscular dystrophy, limb-girdle, type 2G (AR) 983 2 ENST00000309889.2 100
FKTN 607440 9q31.2 Muscular dystrophy-dystroglycanopathy
(limb-girdle), type C, 4 (AR)
7,566 11 ENST00000602661.5 99,68
ANO5 608662 11p14.3 Muscular dystrophy, limb-girdle, type 2L (AR) 6,881 22 ENST00000324559.8 98,75
FKRP 606596 19q13.32 Muscular dystrophy-dystroglycanopathy
(limb-girdle), type C, 5 (AR)
3,514 4 ENST00000318584.9 99,37
SMCHD1 614982 18p11.32 Facioscapulohumeral muscular dystrophy 2,
digenic (AD)
9,152 48 ENST00000320876.10 100
AD, Autosomal Dominant; AR, Autosomal Recessive; XLR, X-linked Recessive.
performed on the father and the maternal uncle of the proband
who resulted completely unaffected.
The present study was approved by the ethics committee
of Santa Lucia Foundation and was performed according to
the Declaration of Helsinki. All participants provided signed
informed consent for genetic analysis, and, in this regard, they
also provided the consent for publication of this case report.
Laboratory Investigations and Diagnostic
Tests
Genomic DNA was extracted from peripheral blood (400 µL)
using MagPurix Blood DNA Extraction Kit and MagPurix
Automatic Extraction System (Resnova) according to the
manufacturer’s instructions. Samples were sequenced using
Ion PGM System and Ion Ampliseq Customized Panel High
Specificity (Thermo Fisher Scientific). The size of the panel was
129.13Kb, which is expected to screen∼99.72% of the total panel
with a minimum coverage of 20X. The panel included 18 genes,
which were selected using scientific literature, GeneReviews
(www.ncbi.nlm.nih.gov/books/NBK1116/) and frequency of
pathogenic variants in the general population. A detailed
description of the NGS panel has been summarized in Table 1.
Libraries construction was performed by Ion AmpliSeqTM
Library Kits 2.0. Approximately 10 ng/µl of starting DNA
were utilized for multiplex PCR reactions. Successively, two
purification steps (using AMPure XP, Beckman Coulter) were
performed to remove unwanted contaminants and a final
PCR was performed. Template amplification and enrichment
steps were performed by Ion PGM Hi-Q OT2 kit-400,
Ion OneTouch 2 System and Ion OneTouch ES (Thermo
Fisher Scientific). Samples were processed by Ion PGM Hi-
Q Sequencing Kit (400 bp, Thermo Fisher Scientific) and
run on Ion 316 Chip v2 (850 flows required) and Ion
PGM Sequencer (Thermo Fisher Scientific). The results were
analyzed using Ion Reporter 4.6 (Thermo Fisher Scientific)
and Integrated Genome Viewer (IGV). The interpretation of
genetic variants was conducted by Human Gene Mutation
Database (HGMD), Leiden Open Variation Database (LOVD),
ClinVar and ExAC. The functional effect of the detected
variants was evaluated by bioinformatic predictive tools,
including Mutation Taster, Varsome, SIFT, PolyPhen 2, SMART,
Human Splicing Finder (HSF). Direct sequencing (BigDye
Terminator v3.1, BigDyeX Terminator and ABI3130, Applied
Biosystems) was performed to confirm genetic variants and
to sequence genomic coding regions with a coverage <20X
(LMNA, Chr1:156106052-156106076; DYSF, Chr2:71753352-
71753502, Chr2:71776385-71776640; SGCB, Chr4:52904225-
52904560; SGCA, Chr17:48243242-48243570).
RESULTS
The NGS analysis of the proband revealed 3 heterozygous
variants (Supplementary Figure 1). Two variants were
localized in CAPN3, namely NM_000070.2 (CAPN3): c.550delA
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(p.Thr184Argfs) and c.1813G>C (p.Val605Leu) in the exons
4 and 16, respectively. The first is a single nucleotide deletion
and is the most common (75% of cases) pathogenic variant in
European Countries (1). As expected, the bioinformatic analysis
classified the c.550delA (rs80338800) as a loss-of-function variant
(p.Thr184Argfs), causing a frameshift of the open reading frame.
The predictive tools (Mutation Taster, HSF, Varsome, PolyPhen
2, SIFT) described the variant as deleterious. In addition, SMART
revealed that the altered protein product lacks the calpain 3
domain and the three “EF-hands” motifs. The first domain
is involved in the signaling pathways of Calpain while the
EF-hands are essential for the Ca++-dependent activation of the
protein (4).
Concerning c.1813G>C, it is a novel missense variant
(p.Val605Leu) which has been predicted to be deleterious (by
Mutation Taster, HSF, Varsome, PolyPhen 2, SIFT) because of a
potential alteration of splicing. This variant is not annotated in
literature or among online databases and it has not been found
in 200 control subjects. Unfortunately, the analysis by SMART
tool did not yield significant results, as the variant is located
within an uncharacterized domain. The segregation analysis of
CAPN3 showed that the mother and the maternal uncle were
both heterozygous for c.550delA, while the father was carrier
of c.1813G>C.
In addition, NGS analysis on the proband revealed the
presence of a novel variant in LMNA, namely NM_170707
(LMNA): c.550C>T (p.Gln184∗). The over-mentioned variant
has been predicted to be a null variant, has not yet been described
in literature or among online databases and it has not been found
in 200 control subjects. Predictive tools (Mutation Taster, HSF,
Varsome, PolyPhen 2, SIFT) described a pathogenic effect of
this variant on the protein product. SMART tool reported that
the altered LMNA protein lacks the filament domain, which is
essential to maintain its structure and function. The segregation
analysis highlighted the presence of the c.550C>T variant only
in the mother, suggesting a possible association with her cardiac
symptomatology and her family history of disease.
According to the criteria established by the American College
of Medical Genetics (ACMG) Standards and Guidelines (23),
c.1813G>C (CAPN3) can be described as a likely pathogenic
variant considering that it is located in a critical domain without
benign variation (PM1); it is absent in ExAc, GnomAD, and 1000
Genome Browser databases (PM2); considering recessive model
of inheritance, it has been detected in trans with a pathogenic
variant (PM3); multiple lines of computational evidence support
a deleterious effect on the gene or gene product (PP3).
Concerning the clinical classification of c.550C>T (LMNA) by
ACMG, it can be designated as a pathogenic variant, since it
is a null variant causing loss of function (p.Gln184∗) in LMNA
(PVS1); it is absent in ExAc, GnomAD, and 1000 Genome
Browser databases (PM2); it is located in a critical domain
without benign variation (PM1); multiple lines of computational
evidence support a deleterious effect on the gene or gene
product (PP3).
CONCLUSIONS
This case report presented a patient affected by LGMD, who was
found to be carrier of mutations not only in CAPN3 (c.550delA
and c.1813G>C) but also in LMNA (c.550C>T). These results
explain the neuromuscular phenotype of the proband because of
CAPN3mutations and highlight a potential risk of cardiovascular
FIGURE 3 | Pedigree showing the positive familiarity for cardiac phenotype inherited by maternal lineage and the transmission of the CAPN3 and LMNA variants
throughout the family members.
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disorders due to the presence of the variant in LMNA and
her positive family history. Given these results, the family
members were subjected to the segregation analysis. In particular,
the mother resulted to be carrier of CAPN3_c.550delA and
LMNA_c.550C>T, respectively. The mother can be considered
as a healthy carrier for the CAPN3_c.550delA pathogenic
mutation associated with calpainopathy. However, the presence
of a novel variant in LMNA may explain her cardiovascular
pathology (bradycardia and syncopal episodes). The absence of
neuromuscular symptomatology in the mother and the peculiar
clinical picture of the proband excluded a possible association
of LMNA_c.550C>T with neuromuscular phenotype, especially
concerning Emery-Dreifuss Muscular Dystrophy (EMD). In
fact, EMD specifically affects vastus lateralis and biceps brachii
muscles which are relatively spared in LGM2A (24, 25).
The maternal uncle was heterozygous only for the
CAPN3_c.550delA, and, as expected, did not show any
neuromuscular or cardiovascular problems. The father resulted
to carry the novel CAPN3_c.1813G>C and, thereby, he
was unaffected. Overall, segregation analysis confirmed the
inheritance of the three mutations of the proband from her
relatives and highlighted a familiarity for cardiomyopathy which
cannot be neglected (Figure 3).
Altogether, these data raise some important considerations.
First, NGS panel in this patient was critical to reach themolecular
diagnosis of calpainopathy, detecting one known mutation and a
second novel variant predicted as pathogenic. Second, NGS panel
allowed the identification of the novel LMNA_c.550C>T variant
in the proband. This result was consistent with the positive family
history and with segregation data, explaining cardiovascular
disease in the mother and, more importantly, recommending
more specific cardiological follow-up in the proband. It is
important to note that cardiological manifestations occurred in
the mother later in age (55 years), so that we can suppose that the
proband could still be in an “asymptomatic cardiological phase.”
However, a variable phenotypic expression of LMNAmutation in
the proband compared to the mother can’t be excluded. All these
data underline the importance of an integrated approach between
clinicians and geneticists, for correct interpretation of results,
proper genetic counseling and, eventually, clinical management
and follow-up. With regards to genetic and familial counseling,
the NGS analysis was also performed on the partner of the
proband, in order to estimate the reproductive risk for the couple.
The partner was negative to all the 18 tested genes, meaning
that he has 1/650 residual risk to be a healthy carrier for LGMD
causative mutations, considering that the test is 84% sensitive.
Taking into consideration the genetic profile of the proband and
the sensitivity of the NGS test, the residual risk for the couple to
have a child affected with calpainopathy is 1/1300. On the other
hand, the LMNA pathogenic variants are transmitted according
an autosomal dominant pattern, meaning that the proband has
50% probability to have heterozygous children. However, the
clinical picture of the offspring cannot be certainly predicted as
the LMNA_c.550C>T is a novel variant and its functional impact
on the phenotype is still unknown.
In conclusion, this case report highlights the clinical utility
of NGS panels to provide accurate LGMD2A diagnosis and
describe complex phenotypes and comorbidities originating
from the inheritance of different mutations in multiple genes.
However, the application of NGS in the clinical practice
should always be combined with a pre- and post-genetic
counseling in order to provide a clear explanation of the
results, the possible implications on patients’ phenotype, the
recurrence risk within the family as well as to explain possible
unexpected findings.
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